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Introduction
Cardiovascular disease (CVD) is the leading cause of 
death in Europe. Despite recent decreases in mortality 
rates in many countries, CVD is responsible for over 
4 million deaths per year, with coronary heart disease 
(CHD) accounting for almost 1.8 million deaths in Europe 
annually. The proportion of all deaths attributable to CVD 
is greater among women (49%) than in men (40%), with 
large geographic inequalities between countries (1).
The main objectives of CVD prevention are to reduce 
morbidity and mortality and increase the chances of a 
longer life expectancy. There is a wealth of scientific 
evidence from observational studies and randomized 
controlled trials demonstrating that lifestyle interventions 
in relation to smoking, diet and exercise, treatment of 
hypertension, hyperlipidaemia, and diabetes, and the use 
of prophylactic drug therapies can reduce morbidity and 
mortality and improve quality of life in people with CHD 
and those at high risk of developing CVD.
The Joint European Societies (JES) guidelines on CVD 
prevention published in 1994, 1998, 2003, 2007, 2012 and 
2016 defined lifestyle and risk factor goals for both patients 
with CHD and those at high risk of developing CVD (2-7). 
The 2012 JES’ guidelines defined the lifestyle and risk factor 
targets for patients with CHD and those at high risk of 
developing CVD: stop smoking, make healthy food choices 
and be physically active; a body mass index (BMI) less than 
25 kg/m2; blood pressure <140/90 mmHg (<140/80 mmHg 
in patients with diabetes mellitus); low-density lipoprotein 
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(LDL) cholesterol <1.8 mmol/L (<70 mg/dL) or at least 50% 
reduction (patients with proven vascular disease and other 
very high risk subjects) and <2.5 mmol/L (<100 mg/dL) in 
high CVD risk individuals, glycated hemoglobin (HbA1c) 
<7.0 mmol/L (<53 mmol/mol) in people with diabetes 
mellitus, and appropriate use of medication for treatment of 
elevated blood pressure, lipids and glucose. In addition, in 
coronary patients, the appropriate use of cardioprotective 
drug therapies is recommended: aspirin or other platelet-
active drugs, beta -blockers, angiotensin-converting enzyme 
(ACE) inhibitors/angiotensin II receptor blockers (ARBs) 
and antithrombotic drugs (6).
Audits of clinical practice provide an objective assessment 
of clinical outcomes and quantify the extent to which the 
standards set in the guidelines on CVD prevention are 
being implemented in every day clinical practice. Guideline 
implementation in Europe was evaluated in four cross 
sectional surveys called EUROASPIRE (European Action 
on Secondary and Primary Prevention by Intervention to 
Reduce Events) starting in 1995–1996 in nine countries 
under the auspices of the Working Group on Epidemiology 
and Prevention, followed by a second and third surveys 
in 1999–2000 in 15 countries, 2006–2008 in 22 countries 
through the Euro Heart Survey programme and in 2012–
2014 in 26 countries under the auspices of the European 
Society of Cardiology, EURObservational Research 
Programme (8-19). The two most recent surveys included 
for the first time individuals free from any manifestations 
of but at high risk of developing CVD because of arterial 
hypertension, dyslipidemia or type 2 diabetes. The aim of 
EUROASPIRE surveys was to describe lifestyle and risk 
factors management in coronary patients and people at high 
risk of developing CVD, and to see whether the practice of 
preventive cardiology had improved by comparison with 
the previous surveys. The fourth EUROASPIRE IV survey 
on Cardiovascular Disease prevention and Diabetes merged 
with the EuroHeart Survey on Diabetes Mellitus (20,21) 
and incorporated an assessment of dysglycaemia in all 
patients.
Methods
In the hospital arm, coronary patients, men and women 
(≥18 and <80 years of age at the time of their index event 
or procedure), with the following first or recurrent clinical 
diagnoses or treatments for CHD were retrospectively 
identified from hospital discharge lists or other sources: (I) 
elective or emergency CABG; (II) elective or emergency 
percutaneous coronary intervention (PCI); (III) acute 
myocardial infarction; and (IV) unstable angina. In the 
primary care arm, men and women (≥18 and <80 years at 
the time of identification, without a history of coronary 
or other atherosclerotic disease, who had been prescribed 
one or more of the following treatments: (I) blood pressure 
lowering drugs and/or (II) lipid lowering drugs and/or (III) 
glucose lowering (diet and/or oral drugs and/or insulin), 
were identified retrospectively from general practice 
records.
Data collection was based on a review of patient’s 
medical notes and a prospective interview and examination 
at least six months after acute coronary event or procedure 
(coronary patients) or start of blood pressure and/or lipid-
lowering and/or glucose lowering therapy (high risk 
individuals), using standardized methods and instruments. 
The methodology used in EUROASPIRE I was duplicated 
in the second, third and forth surveys with standardized 
interviews and measurements and a central laboratory for 
lipid and glucose analyses, so that time trends between 
surveys could be described. 
Results 
Hospital arm
The most recent EUROASPIRE IV survey was undertaken 
in 78 centres from 24 European countries. A total of 7,998 
coronary patients (24% women) were interviewed on average 
1.3 years following their index event (14,15). A total of 16% 
of patients smoked cigarettes, with only one in two (51%) of 
those who smoked before the index event had stopped. Little 
or no physical activity was reported by 60%. The prevalence 
rates of overweight and obesity were alarming in all countries 
with 38% being obese (BMI ≥30 kg/m2) and 58% centrally 
obese (waist circumference ≥102 cm in men or ≥88 cm in 
women). Blood pressure, lipids and glucose control was 
very poor (Figure 1A). Overall, 43% had blood pressure 
≥140/90 mmHg (≥140/80 mmHg in people with diabetes); 
81% had LDL-cholesterol ≥1.8 mmol/L (>70 mg/dL) and 
27% reported having diabetes. The therapeutic control 
of blood pressure was poor, with only half of patients on 
blood pressure lowering medication (53%) being controlled 
(BP <140/90 mmHg; <140/80 mmHg for patients with 
diabetes). In those on lipid-lowering medication just 
over one fifth (21%) had reached the LDL cholesterol 
goal of <1.8 mmol/L. Only 53% of patients with self-
reported diabetes had HbA1c <7.0 mmol/L. The use of 
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cardioprotective medication was as follows: anti-platelets 
94%; beta-blockers 83%; ACE inhibitors/ARBs 75%, and 
statins 86%. Furthermore, only half of coronary patients 
(51%) were advised to participate in a CVD prevention 
and rehabilitation programme and 81% of those advised 
attended at least half of the sessions. 
A comparison across the most recent three surveys 
provided a unique description of time trends for secondary 
prevention in the same countries, geographic areas and 
hospitals over a period of 14 years (16,17). The results 
showed adverse lifestyle trends, a substantial increase in 
obesity, central obesity and diabetes, and high prevalences of 
persistent smoking among younger patients and especially 
women. The prevalence of smoking was virtually unchanged 
over the three surveys with about one in five patients 
still smoking at the time of interview. The prevalence of 
obesity and central obesity increased significantly by 7% 
and 6%, respectively. These adverse trends in body weight 
and distribution most probably contribute to the poor 
control of other risk factors such as raised blood pressure, 
dyslipidemia and diabetes. Although blood pressure and 
lipid management improved these risk factors were still 
not optimally controlled. The proportions of patients 
with raised blood pressure and elevated LDL cholesterol 
decreased significantly by 9% and by 21%, respectively. 
However, many patients on antihypertensive and lipid-
lowering medication had not reached the blood pressure 
and LDL-cholesterol goal. The prevalence of diabetes 
increased by 9% over 14 years reflecting most probably the 
rising prevalence of obesity and central obesity. The glucose 
control in patients with self-reported diabetes remained 
unchanged across the three surveys with only a minority of 
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Figure 1 Therapeutic control of blood pressure, LDL-cholesterol and glucose in people on blood pressure, lipids and glucose-lowering 
treatments, respectively. (A) Coronary patients; (B) people at high CVD risk. LDL, low-density lipoprotein; CVD, cardiovascular disease.
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patients achieving the target of fasting glucose <7.0 mmol/L. 
There appeared to be an apparent ceiling to prescribing 
cardioprotective medication. Although the frequency 
of cardioprotective drug use had substantially increased 
between the EUROASPIRE II and III surveys, no further 
significant change was observed between the third and 
fourth surveys. However, there was a two-fold increase in 
the proportion of patients on high intensity statins between 
the III and IV surveys.
Primary care arm
In the primary care arm, the gap between evidence based 
guidelines and clinical practice was even greater than that 
seen for coronary patients (18,19). A total of 4,579 patients 
(59% women) in EUROASPIRE IV considered to be at 
high cardiovascular risk were interviewed at least 6 months 
after the start of blood pressure, lipid-lowering or glucose 
treatment (18). Overall, 17% smoked cigarettes, 44% were 
obese and 64% centrally obese. The risk factor control was 
inadequate, with only 43% of the patients on blood pressure 
lowering medication reaching the target of <140/90 mmHg 
(<140/80 mmHg in people with self-reported diabetes) 
and a third (33%) of those on lipid-lowering medication 
achieving the LDL-cholesterol target of <2.5 mmol/L 
(Figure 1B) Glucose control among people with diabetes 
was unsatisfactory, with less than two thirds (59%) achieving 
the HbA1c target of <7.0%. In addition many patients 
without any blood pressure and/or lipid lowering therapy 
had elevated blood pressure (46%) and elevated LDL-
cholesterol (89%). 
The comparison between EUROASPIRE III and IV 
demonstrated that there were no major differences between 
the two surveys in lifestyle and risk factor management in 
people at high risk of developing CVD (19). The prevalence 
of smoking was similar in both surveys. However the 
proportion of smokers who did not intend to quit was 
significantly greater in EUROASPIRE IV compared 
with EUROASPIRE III. The prevalence of overweight 
or obesity was high and identical in both surveys. No 
significant differences were observed in physical activity. In 
subjects with known arterial hypertension blood pressure 
was at or below guideline recommended targets in 28% in 
the third and 35% in the fourth survey. In people on lipid 
lowering drugs the LDL-C was <2.5 mmol/L in 28% and 
37%, respectively. In participants with known diabetes 
HbA1c was <7.0% in 62% in the third and 60% in the 
fourth survey.
Discussion
The EUROASPIRE results showed that implementation 
of evidence-based guidelines on CVD prevention is far 
from optimal. A large majority of coronary and high CVD 
patients in Europe did not achieve the guideline standards 
set by the 2012 JES’ guidelines on CVD prevention 
in clinical practice, with high prevalences of persistent 
smoking, overweight, obesity and diabetes. Although, 
most patients were receiving cardioprotective drugs, blood 
pressure, lipids and diabetes control was inadequate. There 
was considerable variation between European countries 
in patients’ lifestyle, risk factor prevalences and use of 
cardioprotective medication.
There is a wealth of scientific evidence that cardiac 
rehabilitation is an effective treatment for patients with 
CHD and reduces both cardiac and total mortality (22-24). 
A systematic review of 47 studies including 10,794 patients 
randomized to exercise-based cardiac rehabilitation or usual 
care demonstrated that exercise-based cardiac rehabilitation 
was effective in reducing total and cardiovascular mortality 
in medium to longer term studies by 13% and 26%, 
respectively, and hospital admissions in shorter term studies 
by 31% (23). The contribution of secondary prevention 
programs with or without exercise was evaluated in a meta-
analysis of 63 randomized controlled trials including 21,295 
patients with CHD (24). Secondary prevention programs 
reduced all-cause mortality by 15%, and for recurrent 
myocardial infarction by 17%. The effects on mortality 
and myocardial infarction were similar for programs 
without exercise, programs with exercise and exercise only 
programs. 
The results of EUROASPIRE survey showed that despite 
the wealth of scientific evidence only half of patients were 
referred to attend a cardiac rehabilitation programme and 
only two-fifths participated in such a programme. So, there 
is considerable potential to further reduce the risk of CVD 
in existing cardiac rehabilitation programs. Recent studies, 
such as EUROACTION and Global Secondary Prevention 
Strategies to Limit (GOSPEL) studies, provided scientific 
evidence for the beneficial effect and improved prognosis 
in patients with CHD (25,26). A health economics analysis 
from EUROASPIRE III showed favorable results with 
an average incremental cost-effectiveness ratio (ICER) of 
Euro12,484 per quality-adjusted life year (QALY) (27).
Lifestyle modifications (smoking cessation, healthy 
eating and becoming physically active), together with 
effective management of blood pressure and lipids can also 
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reduce the risk of coronary or other atherosclerotic disease 
in people at high CVD risk. Yet, despite the scientific 
evidence, it is surprising that people living with high risk for, 
but still no manifestations of CVD get such unsatisfactory 
protection from future illness. The EUROASPIRE results 
strongly underlines that intense efforts must be taken 
not only to issue and update guidelines on cardiovascular 
prevention but also to enhance their implementation. 
Therefore, all high CVD risk patients should be offered 
a structured, multidisciplinary prevention program that 
gives an opportunity for a comprehensive evaluation and 
cardiovascular risk reduction.
Optimal control of CVD risk factors is one of the most 
effective methods for reducing vascular events in patients 
with CHD and in people at high CVD risk. All of them 
should receive professional advice on stopping smoking, 
healthy diet and how to increase their physical activity. The 
risk of future CVD can be further reduced by optimizing 
the prescription of cardioprotective medication, combining 
different drugs and up-titrating them to the doses 
showing efficacy and safety in clinical trials. Improving 
treatment adherence is a very important step in optimizing 
cardiovascular risk factor management. In clinical practice, 
physicians should always assess treatment adherence and 
identify reasons for non-adherence. 
Conclusions
Preventive cardiology needs a systematic, comprehensive, 
multidisciplinary approach, which addresses lifestyle 
and risk factor management by cardiologists, general 
practitioners, nurses and other allied health professionals, 
and a health care system which invests in prevention. What 
is required is a comprehensive risk reduction approach 
to lifestyle, risk factor and therapeutic management to 
reduce total cardiovascular risk. A modern cardiovascular 
prevention program could be created by integrating ‘cardiac 
rehabilitation’ and ‘secondary prevention’ to deliver one 
comprehensive risk reduction service. All coronary and 
high CVD risk people require a comprehensive preventive 
cardiology programme, combining a professional lifestyle 
intervention with effective risk factor management to 
achieve better risk factor control and adherence with 
cardioprotective medications, and to reduce the risk of 
future cardiovascular events.
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